Nature Communications (Aug 2020)
A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response
- A. Ari Hakimi,
- Kyrollis Attalla,
- Renzo G. DiNatale,
- Irina Ostrovnaya,
- Jessica Flynn,
- Kyle A. Blum,
- Yasser Ged,
- Douglas Hoen,
- Sviatoslav M. Kendall,
- Ed Reznik,
- Anita Bowman,
- Jason Hwee,
- Christopher J. Fong,
- Fengshen Kuo,
- Martin H. Voss,
- Timothy A. Chan,
- Robert J. Motzer
Affiliations
- A. Ari Hakimi
- Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
- Kyrollis Attalla
- Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
- Renzo G. DiNatale
- Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
- Irina Ostrovnaya
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center
- Jessica Flynn
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center
- Kyle A. Blum
- Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
- Yasser Ged
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Douglas Hoen
- Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center
- Sviatoslav M. Kendall
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center
- Ed Reznik
- Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center
- Anita Bowman
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Jason Hwee
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Christopher J. Fong
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Fengshen Kuo
- Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center
- Martin H. Voss
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Timothy A. Chan
- Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center
- Robert J. Motzer
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- DOI
- https://doi.org/10.1038/s41467-020-17965-0
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 11
Abstract
The clinical benefit from immunotherapy response in patients with mutations of genes forming the chromatin remodelling complex PBAF remains controversial. Here the authors show that PBAF complex mutations are not associated with favourable response in pan-cancer cohorts of patients treated with immune-checkpoint blockade.
